Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

Maria Tariq Siddiqui; Allyson Price; Alessandra Ferrajoli; Gautam Borthakur

doi:10.1016/j.lrr.2021.100266

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax

Leuk Res Rep. 2021 Aug 30:16:100266. doi: 10.1016/j.lrr.2021.100266. eCollection 2021.

Authors

Maria Tariq Siddiqui¹, Allyson Price¹, Alessandra Ferrajoli¹, Gautam Borthakur¹

Affiliation

¹ The Department of Leukemia, MD Anderson Cancer Center, Houston, TX, United States.

Abstract

B cell prolymphocytic leukemia is a rare and aggressive disorder often with high risk features including TP53 mutation, deletion 17p and complex karyotype. There is scarcity of data regarding treatment and existing therapies induce short lived remissions. Ibrutinib, a Bruton tyrosine kinase inhibitor, has had success in some patients with high risk features. Venetoclax, a BCL-2 inhibitor, has primarily been used in the relapsed setting. We present a case of B PLL with deletion 17p and mutated TP53 treated with ibrutinib and venetoclax in the frontline setting which resulted in measurable/minimal residual disease negative remission for approximately three years.

Keywords: B cell prolymphocytic leukemia; Deletion 17p; Ibrutinib; TP53; Venetoclax.

Publication types

Case Reports